Lu Y, Smith ER, McEvoy R, et al. JAMA Netw Open. 2026;9(9):e2634788. doi:10.1001/jamanetworkopen.2026.34788
Key Points
Question What is the estimated effectiveness of the respiratory syncytial virus (RSV) vaccines against RSV-related hospitalization and death among US adults 65 years or older?
![]() |
| Forest Plot of Vaccine Effectiveness (VE) Estimates and Respiratory Syncytial Virus (RSV)–Related Death Outcomes |
Meaning This study suggests that both RSV vaccines provided substantial protection among US older adults across all ages 65 years or older and for immunocompromised individuals.
Importance Respiratory syncytial virus (RSV) causes a substantial number of hospitalizations and deaths among older adults. Two RSV vaccines for individuals aged 60 years or older were approved in 2023; it was important to monitor their clinical effectiveness during routine care in the first RSV season after regulatory approval.





